The short version of this quarter's tesamorelin news: nothing changed what the medicine is approved to treat, what its label says, or what the main studies show. The news happened around it: FDA named tesamorelin in all five of its August warning letters to online peptide sellers, WADA kept it on sport's prohibited list for 2027, and three new papers added detail without moving the big picture.
As of September 22, 2026, the day this article was written, the brand's prescribing information still carried its earlier revision dates, and the only new trial result since June came from a 22-person pilot study.
Changelog
September 21 — WADA's 2027 list keeps tesamorelin prohibited. The World Anti-Doping Agency's 2027 Prohibited List, published September 21 and in force from January 1, 2027, still names tesamorelin in section S2.2.4, growth hormone releasing factors, among substances prohibited at all times, just as it was in 2026. For a tested athlete, a prescription alone does not settle it; WADA's route is a therapeutic use exemption, formal permission to use a prohibited substance for a documented medical need.
September 1 — FDA posted five warning letters, each naming tesamorelin. In letters dated August 24, FDA told five online peptide sellers that their tesamorelin products were unapproved new drugs, judging by how the websites presented them. Two letters also named tesamorelin and ipamorelin blends (one of the five letters). A warning letter is a formal notice to one company, not a court ruling or a rule about the molecule. What the five letters mean covers them in full.
July 31 — a meta-analysis pooled the HIV trials. A meta-analysis combines earlier trials into one estimate. This one pooled four randomized trials with 909 people with HIV-associated lipodystrophy, a shift in where the body stores fat during HIV treatment. Tesamorelin groups averaged about 21 square centimeters less visceral fat on CT than placebo groups, and 1.4 kg more lean mass. More people stopped treatment on tesamorelin, though not by a statistically significant margin, and the authors called long-term safety data limited (Ditta et al., Journal of the International Association of Providers of AIDS Care, 2026).
July 29 — the brand labels were re-posted, not rewritten. DailyMed shows the Egrifta WR label and the older Egrifta SV label as "Updated July 29, 2026," but the prescribing information's own revision line still reads 3/2025 for Egrifta WR and 2/2024 for Egrifta SV. Egrifta WR's indication reads word for word as it did in March 2025.
July 23–24 — tesamorelin was not on FDA's compounding panel agenda. The Pharmacy Compounding Advisory Committee discussed seven other peptides, including BPC-157, TB-500 and MOTS-c, so nothing decided there applied to tesamorelin.
July 8 — a new trial published its plan. A protocol is the plan a trial commits to before any results exist. TRIUMPH is enrolling 100 sedentary adults aged 50 to 80 living with HIV who are frail or at risk of frailty and carry excess abdominal fat. They are randomized to tesamorelin or placebo alongside home exercise for 24 weeks, then followed to week 48 (Erlandson et al., BMJ Open, 2026). It is listed as recruiting, with no results yet.
June 17 — a small cognition pilot found no clear change. Twenty-two adults whose thinking ranged from normal to mild cognitive impairment received low-dose tesamorelin (1 mg) or placebo for 10 weeks. Treatment was not linked with significant changes in body composition, sleep, physical performance, glucose tolerance or cognitive scores. A machine-learning look at brain scans flagged possible differences, which is a lead for future work, not a result (Stewart et al., eNeurologicalSci, 2026).
What this tesamorelin news does not change
Tesamorelin is a GHRH analogue: a lab-made version of growth hormone-releasing hormone, the signal that tells the pituitary gland to release the body's own growth hormone. It is not growth hormone itself. Its effects run through that release and through IGF-1, a growth factor the liver makes in response, which is why IGF-1 is the lab number a provider watches.
The core evidence has not moved. In a 2007 trial of 412 adults with HIV and excess abdominal fat, visceral fat, the deep fat packed around the organs, fell 15.2% over 26 weeks on tesamorelin and rose 5.0% on placebo, measured by CT (Falutz et al., New England Journal of Medicine, 2007). A pooled analysis of the two phase 3 trials, 806 people in all, put the treatment effect at 15.4% at 26 weeks, with no significant change in the fat just under the skin (Falutz et al., Journal of Clinical Endocrinology & Metabolism, 2010).
The tesamorelin clinical trials guide walks through every study, and tesamorelin for belly fat explains why visceral fat is not the fat you can pinch. The label keeps its limits too: Egrifta WR is not indicated for weight loss management, because its effect on weight is neutral, and its long-term cardiovascular safety has not been established.
Where the tesamorelin and ipamorelin blend fits
The warning letters also named blends, so it is worth being clear about them. Ipamorelin reaches the pituitary through a different door, the ghrelin receptor, which is why the pairing makes pharmacological sense. No published trial has tested the two together, and every number above comes from tesamorelin on its own. Tesamorelin and ipamorelin together sets out that gap in detail.
A blend is also its own preparation. The prescription and the pharmacy's label say what is in it and how much; the tesamorelin trials cannot.
Tesamorelin and the FDA in 2026
The brand, Egrifta, has one labeled use: reducing excess abdominal fat in adults with HIV and lipodystrophy. Its newest form, Egrifta WR, came through a March 25, 2025 supplement with that same use. Even the two brand forms are not interchangeable: the label says Egrifta WR and Egrifta SV are not substitutable, because their strength, mixing and storage differ.
Tesamorelin offered through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Why compounded tesamorelin is not FDA-approved covers the brand's full history.
Regulatory status is one part of a clinical decision, not a marketing gate. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
What a provider considers now
The questions did not change this quarter. The Egrifta label's contraindications are where a review starts: pregnancy, active cancer, a known allergy to tesamorelin, and disruption of the hypothalamic-pituitary axis, such as pituitary surgery or disease, a pituitary tumor, head radiation or head injury. Its warnings include elevated IGF-1, fluid retention, glucose intolerance or diabetes, allergic reactions and injection-site reactions. So a provider asks about cancer history, blood sugar, current medicines and what the person is hoping for, and sets any formulation and dose from there.
At Promise, a licensed provider reviews every request and not everyone qualifies.
The August letters show the alternative clearly. The products in them were sold straight from websites and labeled for laboratory use, not dispensed on a prescription. A prescribed route has a clinician who reviewed the person, a licensed U.S. compounding pharmacy whose label says what is in the vial, and a path for reporting a side effect. The quickest way to tell the two apart is to ask who prescribed it and which pharmacy filled it.
What to watch next
Four things would change the next edition: TRIUMPH's results, an Egrifta label with a new revision date, an FDA agenda item or action that names tesamorelin, and responses or close-out letters on the five warning-letter pages. Until then, the careful reading holds: the label is real and narrow, the visceral-fat data in adults with HIV are solid, and the evidence for everything else people attach to the name is thinner.